Real-world experience with trabectedin for the treatment of recurrent ovarian cancer

References

• Lord R, Rauniyar J, Morris T, et al. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. Int J Gynecological Cancer. 2020;30(7):1026–1033.
   PubMed Web of Science ®Google Scholar
• Oberaigner W, Minicozzi P, Bielska-Lasota M, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncologica. 2012;51(4):441–453.
   PubMed Web of Science ®Google Scholar
• Cannistra S, Bast R Jr, Berek J, et al. Progress in the management of gynecologic cancer: consensus summary statement. J clin oncol. 2003;21(10):129–132.
   PubMedGoogle Scholar
• Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J clin oncol. 2010;28(20):3323–3329.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Galmarini CM, D’Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77(4):663–671.
   PubMed Web of Science ®Google Scholar
• Mascilini F, Amadio G, Di Stefano MG, et al. Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. Onco Targets Ther. 2014;7:1273–1284.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(8):61–65.
   Google Scholar
• Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11). DOI:https://doi.org/10.1093/jnci/djx187
   PubMedGoogle Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - What is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102(6):924–933.
   PubMed Web of Science ®Google Scholar
• Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16(5):312–325.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Public summary of opinion on orphan designation trabectedin for the treatment of ovarian cancer. [cited 2020 Mar 31]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005561.pdf
   Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J clin oncol. 2010;28(19):3107–3114.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361–2368.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Ghatage P, Parekh T, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015;26(5):914–920.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020;156(3):535–544.
   PubMed Web of Science ®Google Scholar
• Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer interGroup: recurrent disease. Ann Oncol. 2017;28(4):727–732.
   PubMed Web of Science ®Google Scholar
• Monk B, Herzog T, McGowan T, et al. Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC). Ann Oncol. 2020;31(4):S625.
   Google Scholar
• Selle F, Heudel PE, Hardy-Bessard AC, et al. GINECO prospective non-interventional PROSPECTYON study: trabectedin plus pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian cancer. Anticancer Res. 2020;40(7):3939–3945.
   PubMed Web of Science ®Google Scholar
• Runnebaum IB, Reichert D, Ringsdorf U, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. J Cancer Res Clin Oncol. 2018;144(6):1185–1195.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Villanucci A, et al. A European, observational, prospective trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian cancer. Oncologist. 2021;26(4):e658–68.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Salutari V, Vincenzi B, et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Gynecol Oncol. 2013;130(3):505–510.
   PubMed Web of Science ®Google Scholar
• Nicoletto MO, Baldoni A, Casarin A, et al. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. Tumori. 2015;101(5):506–510.
   PubMed Web of Science ®Google Scholar
• Moriceau G, Rivoirard R, Méry B, et al. Real-world outcomes of combination chemotherapy with trabectedin plus pegylated liposomal doxorubicin in patients with recurrent ovarian cancer: a single-center experience. Chemotherapy. 2016;61(3):122–126.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Musella A, Romito A, et al. Short-infusion trabectedin in heavily pretreated ovarian cancer patients: a single-institution experience. Oncology. 2017;93(6):359–366.
   PubMed Web of Science ®Google Scholar
• Adam JP, Boumedien F, Letarte N, et al. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2017;147(1):47–53.
   PubMed Web of Science ®Google Scholar
• Villanucci A, Tavella K, Vannini L, et al. Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. Mol Clin Oncol. 2018;9(6):635–639.
   PubMed Web of Science ®Google Scholar
• Romero I, Mallol P, Santaballa A, et al. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. Anticancer Drugs. 2019;30(6):628–635.
   PubMed Web of Science ®Google Scholar
• Casado A, Callata HR, Manzano A, et al. Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer. Future Oncol. 2019;15(3):271–280.
   PubMed Web of Science ®Google Scholar
• Tahir S. Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer. EJC Suppl. 2014;12(2):17–20.
   PubMedGoogle Scholar
• Colombo N, Hardy-Bessard AC, Ferrandina G, et al. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. Expert Rev Anticancer Ther. 2016;16(1):11–19.
   PubMedGoogle Scholar
• Rubio Pérez MJ. Effect of the combination of trabectedin and pegylated liposomal doxorubicin in a BRCA2 mutation carrier with recurrent platinum-sensitive ovarian cancer. Case Rep Oncol. 2017;10(2):433–437.
   PubMed Web of Science ®Google Scholar
• Marth C. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study. Expert Rev Anticancer Ther. 2018;18(1):19–22.
   PubMedGoogle Scholar
• Ray-Coquard I. Management of relapsed ovarian cancer in routine clinical practice: a case study. Expert Rev Anticancer Ther. 2018;18(1):9–11.
   PubMedGoogle Scholar
• Colombo N. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line. Expert Rev Anticancer Ther. 2018;18(1):13–17.
   PubMedGoogle Scholar
• Guerra Alía EM, Sempere Ortega C, Cortés Salgado A, et al. Maintenance with trabectedin in the treatment of platinum-sensitive recurrent ovarian cancer. Case Rep Oncol. 2019;12(2):447–455.
   PubMed Web of Science ®Google Scholar
• Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48.
   PubMed Web of Science ®Google Scholar
• Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;207084:2010.
   Google Scholar
• Pignata S, Cecere C, Du Bois A, et al. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28(8):51–56.
   Google Scholar
• Ventriglia J, Paciolla I, Cecere SC, et al. Trabectedin in ovarian cancer: is it now a standard of care? Clin Oncol R Coll Radiol. 2018;30(8):498–503.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol. 2012;23(10):128–131.
   Google Scholar
• Poveda A, Ray-Coquard I, Romero I, et al. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat Rev. 2014;40(3):366–375.
   PubMed Web of Science ®Google Scholar
• Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J clin oncol. 2004;22(15):3120–3125.
   PubMed Web of Science ®Google Scholar
• Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep. 2011;13(6):459–471.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Dalton H, Benjamin I, et al. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des. 2012;18(25):3754–3769.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I. Trabectedin mechanism of action and platinum resistance: molecular rationale. Future Oncol. 2017;13(23):17–21.
   PubMed Web of Science ®Google Scholar
• Tomao F, D’Incalci M, Biagioli E, et al. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality? Cancer. 2017;123(18):3450–3459.
   PubMed Web of Science ®Google Scholar
• Colombo N. When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. Future Oncol. 2017;13(23):23–29.
   PubMed Web of Science ®Google Scholar
• Colmegna B, Uboldi S, Frapolli R, et al. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br J Cancer. 2015;113(12):1687–1693.
   PubMed Web of Science ®Google Scholar
• Colombo N, Gadducco A, Sehouli J, et al. LBA30 INOVATYON study: randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Ann Oncol. 2020;31(4):S1161.
   Google Scholar
• Alvarez RD, Matulonis UA, Herzog TJ, et al. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016;141(3):405–409.
   PubMed Web of Science ®Google Scholar
• Boussios S, Mikropoulos C, Samartzis E, et al. Wise management of ovarian cancer: on the cutting edge. J Pers Med. 2020;10(2):41.
   PubMed Web of Science ®Google Scholar
• Biondani P, Boudjemai A, Blanchet de La Lande C, et al. Complete response to trabectedin in combination with pegylated liposomal doxorubicin (PLD) in heavily pre-treated BRCA-2 mutated platinum-sensitive intermediate epithelial ovarian cancer (EOC). Int J Gynecological Cancer. 2015;25(1):1297.
   Google Scholar
• Giovannoni S, Marchetti C, Verkhovskaia S, et al. Long-lasting complete response with trabectedin plus pegylated liposomal doxorubicin (PLD) in a young BRCA-mutated woman with platinum-sensitive relapsed ovarian cancer (ROC): a case report. Int J Gynecological Cancer. 2015;25(19):1358.
   Google Scholar
• Ray-Coquard I, Mirza MR, Pignata S, et al. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: comparison of active surveillance and maintenance treatment. Cancer Treat Rev. 2020;90:102107.
   PubMed Web of Science ®Google Scholar
• Pignata S, Cecere SC. How to sequence treatment in relapsed ovarian cancer. Future Oncol. 2021;17(3s):1–8.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38(1):181–193.
   PubMed Web of Science ®Google Scholar